A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A [TRX-1] in Patients With Rheumatoid Arthritis

Trial Profile

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A [TRX-1] in Patients With Rheumatoid Arthritis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs TRX 1-Tolerx (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 06 Mar 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Aug 2010 Results presented at the 11th Annual Congress of the European League Against Rheumatism in June 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top